HeartBeam, Inc. Form 8-K Summary
Business context and reporting period
HeartBeam, Inc. filed a Current Report on Form 8-K dated December 20, 2021, reporting the appointment of Alan Baumel, effective December 20, 2021. The filing was signed on December 23, 2021. The company is an emerging growth company, and its common stock and warrants trade on Nasdaq under BEAT and BEATW.
Key financial and operating terms
- Mr. Baumel was appointed Chief Operating Office, as stated in the filing.
- His employment agreement provides for annual compensation of $200,000, payable semi-monthly.
- Compensation may be adjusted under the company’s employee compensation policies, and Mr. Baumel is eligible for employee benefits.
- Following the closing of the company’s initial public offering, he will be eligible for the company’s bonus program.
- Subject to Board or Compensation Committee approval, the agreement allows for an option to purchase shares representing 1% of the company’s post-IPO common stock, subject to the applicable vesting schedule.
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other period-specific financial results.
Material changes, outlook, risks, and unusual items
- The material change is the appointment of a senior MedTech executive with experience in product development, manufacturing, quality assurance, regulatory affairs, and medical-device operations.
- Mr. Baumel previously held senior roles at Bardy Diagnostics, W. L. Gore & Associates, Ablation Frontiers, and Cameron Health, among other organizations.
- The filing does not provide financial guidance, operating forecasts, new risk disclosures, contingencies, or management commentary regarding the company’s outlook.
- The employment agreement’s description in the Form 8-K is not complete; the full agreement is filed as Exhibit 10.1.
- The company disclosed that there are no reportable related-party transactions involving Mr. Baumel and no family relationship with current officers or directors.
Important facts for investors to verify
- Review Exhibit 10.1 for the complete employment terms, including the option’s vesting schedule, termination provisions, and other rights and obligations.
- Confirm the exact title and scope of Mr. Baumel’s position, as the filing states “Chief Operating Office.”
- Assess the potential dilution associated with the option for 1% of post-IPO common stock and the conditions for its approval and issuance.
- Review Exhibit 99.1, the December 22, 2021 press release, which the filing references as announcing the appointment or appointments.